ERBB2 and breast cancer: In both HR+/HER2+ and HR−/HER2+ BC patients, compared with T1, only T4 significantly increased the probability of developing BM (p = 0.031, p < 0.001, respectively), whereas T2 and T3 did not significantly increase the risk of BM (p > 0.05 for all variables).